<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007341</url>
  </required_header>
  <id_info>
    <org_study_id>KC16MISI0042</org_study_id>
    <nct_id>NCT04007341</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on the Inflammatory Response After One-lung Ventilation</brief_title>
  <official_title>Effect of Dexmedetomidine on the Inflammatory Response in Patients Undergoing Lung Resection Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The postoperative inflammatory response is significant in lung resection surgery because of
      major operation and one-lung ventilation. Dexmedetomidine has been shown to reduce
      pro-inflammatory cytokine levels and improve clinical outcomes. The aim of this study was to
      determine the effects of dexmedetomidine on inflammatory responses after lung resection
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2018</start_date>
  <completion_date type="Actual">January 18, 2019</completion_date>
  <primary_completion_date type="Actual">January 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin (IL)-6</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Blood samples were collected from the antecubital vein</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the saline group were infused with an identical volume of normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective video-assisted thoracoscopic surgery (VATS) lobectomy

          -  20 &lt; age &lt; 75

          -  American Society of Anesthesiologists (ASA) classification I~II

        Exclusion Criteria:

          -  preoperative inflammation (CRP&gt;10ng/#, WBC&gt;10,000/mm3, body temperature &gt;38#)

          -  steroid administration within 1 month

          -  hematologic / autoimmune disease

          -  congestive heart failure (NYHA class III~IV) or significant arrhythmia

          -  severe obstructive / restrictive pulmonary disease

          -  previous history of thoracic surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Wonjung Hwang</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

